SGN-STNV / Pfizer - LARVOL DELTA

SGNSTNV-001: A Study of SGN-STNV in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=111 | Terminated | Sponsor: Seagen Inc. | Trial completion date: Mar 2026 ➔ Mar 2024 | Active, not recruiting ➔ Terminated | Trial primary completion date: Mar 2025 ➔ Mar 2024; Study closed due to portfolio prioritization

Metastases • Trial completion date • Trial primary completion date • Trial termination • Appendix Cancer • Breast Cancer • Cervical Cancer • Colorectal Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • Uterine Cancer • HER-2

SGNSTNV-001: A Study of SGN-STNV in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=111 | Active, not recruiting | Sponsor: Seagen Inc. | Recruiting ➔ Active, not recruiting | N=360 ➔ 111

Enrollment change • Enrollment closed • Metastases • Appendix Cancer • Breast Cancer • Cervical Cancer • Colorectal Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • Uterine Cancer • HER-2

SGNSTNV-001: A Study of SGN-STNV in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=315 | Recruiting | Sponsor: Seagen Inc. | Trial completion date: Dec 2023 ➔ Mar 2026 | Trial primary completion date: Dec 2022 ➔ Mar 2025

Metastases • Trial completion date • Trial primary completion date • Appendix Cancer • Breast Cancer • Cervical Cancer • Colorectal Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • Uterine Cancer • HER-2

[VIRTUAL] A phase I study of SGN-STNV, a novel antibody–drug conjugate targeting sialyl-thomsen-nouveau antigen (STn), in adults with advanced solid tumors (SGNSTNV-001) (ESMO 2021) - P1 | "Patients must have an Eastern Cooperative Oncology Group performance status score of 0 or 1 and measurable disease per RECIST version 1.1. Study accrual is ongoing in the USA, Canada, and Europe."

Clinical • P1 data • Appendix Cancer • Breast Cancer • Cervical Cancer • Colorectal Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • HER-2 • MUC1 • MUC16

SGNSTNV-001: A Study of SGN-STNV in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=315 | Recruiting | Sponsor: Seagen Inc. | N=225 ➔ 315

Enrollment change • Appendix Cancer • Breast Cancer • Cervical Cancer • Colorectal Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • Uterine Cancer • HER-2

A Study of SGN-STNV in Advanced Solid Tumors (clinicaltrials.gov) - P1; N=205; Recruiting; Sponsor: Seagen Inc.; Not yet recruiting ➔ Recruiting

Enrollment open • Appendix Cancer • Breast Cancer • Cervical Cancer • Colorectal Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • HER-2

[VIRTUAL] Targeting Sialyl-Thomsen nouveau (STn) antigen with the SGN-STNV antibody-drug conjugate is effective in preclinical studies (AACR 2021) - "SGN-STNV was well tolerated in non-human primates (NHP), with no concerning target-mediated toxicities and a maximum tolerated dose similar to other vedotin-platform ADCs. In summary, the antibody specificity, unique mechanism of targeting a carbohydrate, anti-tumor activity, and tolerability provide a strong rationale for initiation of a phase I study to investigate the therapeutic potential of SGN-STNV."

Preclinical • Colorectal Cancer • Endometrial Cancer • Gastric Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • CD44 • MUC1 • MUC16 • MUC5AC

Seagen to Highlight Data from Novel Targeted Therapies at AACR (Businesswire) - “Seagen…announced that preclinical data from its pipeline of novel targeted oncology drugs will be presented at the American Association for Cancer Research (AACR) Annual Meeting being held April 10-15, 2021…‘Our research being presented at AACR describes intriguing preclinical data for three novel pipeline programs that are in ongoing clinical trials. This includes SEA-TGT, an anti-TIGIT antibody using our SEA technology, and two vedotin-based ADCs, SGN-B6A and SGN-STNV…‘Among the findings, we will show the enhanced therapeutic effect in combining SEA-TGT with a checkpoint inhibitor or a vedotin-based ADC across different tumor models. In addition, we will report for the first time our preclinical data with SGN-STNV, a novel ADC targeting a carbohydrate antigen that may have broad applicability across solid tumors.”

Preclinical • Gastrointestinal Cancer • Gynecologic Cancers • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor

Seagen Reports Fourth Quarter and Full Year 2020 Financial Results (Businesswire) - "...the first patient was dosed in a phase 1 trial of SGN-STNV, a novel antibody-drug conjugate (ADC) targeting Sialyl Thomsen-nouveau (STN). STN is highly expressed across multiple solid tumors."

Trial status • Oncology • Solid Tumor

A Study of SGN-STNV in Advanced Solid Tumors (clinicaltrials.gov) - P1; N=205; Not yet recruiting; Sponsor: Seagen Inc.

New P1 trial • Appendix Cancer • Breast Cancer • Cervical Cancer • Colorectal Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor